Literature DB >> 18276025

Remote periconditioning reduces myocardial no-reflow by the activation of K ATP channel via inhibition of Rho-kinase.

Jing-Lin Zhao1, Yue-Jin Yang, Wei-Dong Pei, Yu-Hua Sun, Shi-Jie You, Run-Lin Gao.   

Abstract

UNLABELLED: Remote periconditioning is induced by brief cycles of ischemia and reperfusion of a remote organ applied during sustained myocardial ischemia. It remains unknown whether the remote periconditioning reduces myocardial no-reflow. The adenosine triphosphate-sensitive potassium (K(ATP)) channel opening and inhibition of Rho-kinase may be the important mechanism of protection against myocardial no-reflow. Therefore, this study was sought to assess the effect of remote periconditioning on myocardial no-reflow and explore the possible mechanism.
METHODS: Coronary ligation area and area of no-reflow were determined with pathological means in 58 mini-swines randomized into 7 study groups: 9 controls, 8 in remote periconditioning, 8 in hydroxyfasudil (a specific inhibitor of Rho-kinase)-treated, 9 in glibenclamide (K(ATP) channel blocker)-treated, 8 in remote periconditioning and glibenclamide, 8 in hydroxyfasudil and glibenclamide and 8 sham-operated. The ischemia and reperfusion model was created with 3 h of left anterior descending artery occlusion followed by 2 h of reperfusion.
RESULTS: Compared with the control group, remote periconditioning decreased Rho-kinase activity (P<0.01), increased coronary blood volume (P<0.05), decreased area of no-reflow (from 82.3+/-3.9% to 45.5+/-5.7% of ligation area, P<0.01) and reduced necrosis size (from 98.5+/-1.3% to 74.7+/-6.3% of ligation area, P<0.05). Hydroxyfasudil had the same effect on the above parameters as remote periconditioning. Glibenclamide abrogated the effect of remote periconditioning or hydroxyfasudil on area of no-reflow and necrosis area, but not Rho-kinase activity.
CONCLUSION: Remote periconditioning can reduce myocardial no-reflow after ischemia and reperfusion. This beneficial effect could be due to its activation of K(ATP) channel via inhibition of Rho-kinase.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18276025     DOI: 10.1016/j.ijcard.2007.12.024

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  7 in total

Review 1.  KATP Channels in the Cardiovascular System.

Authors:  Monique N Foster; William A Coetzee
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

Review 2.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

Review 3.  Rho kinase as a therapeutic target in cardiovascular disease.

Authors:  Michelle Surma; Lei Wei; Jianjian Shi
Journal:  Future Cardiol       Date:  2011-09

4.  High-dose fasudil preserves postconditioning against myocardial infarction under hyperglycemia in rats: role of mitochondrial KATP channels.

Authors:  Taiga Ichinomiya; Sungsam Cho; Ushio Higashijima; Shuhei Matsumoto; Takuji Maekawa; Koji Sumikawa
Journal:  Cardiovasc Diabetol       Date:  2012-03-22       Impact factor: 9.951

5.  The role of arginase and rho kinase in cardioprotection from remote ischemic perconditioning in non-diabetic and diabetic rat in vivo.

Authors:  Attila Kiss; Yahor Tratsiakovich; Adrian T Gonon; Olga Fedotovskaya; Johanna T Lanner; Daniel C Andersson; Jiangning Yang; John Pernow
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

6.  Label-free cell phenotypic profiling decodes the composition and signaling of an endogenous ATP-sensitive potassium channel.

Authors:  Haiyan Sun; Ying Wei; Huayun Deng; Qiaojie Xiong; Min Li; Joydeep Lahiri; Ye Fang
Journal:  Sci Rep       Date:  2014-05-12       Impact factor: 4.379

7.  Nicorandil regulates the macrophage skewing and ameliorates myofibroblasts by inhibition of RhoA/Rho-kinase signalling in infarcted rats.

Authors:  Tsung-Ming Lee; Shinn-Zong Lin; Nen-Chung Chang
Journal:  J Cell Mol Med       Date:  2017-11-09       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.